Patent · US Expired

N-2 substituted purines

US6166199A · kind A · utility

93Cited by
16References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 4, 1998
Grant dateDec 26, 2000
Priority date
Expiry dateAug 4, 2018

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/3533
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This invention presents novel purine-based compounds for inclusion into oligonucleotides. The compounds of the invention, when incorporated into oligonucleotides are especially useful as "antisense" agents--agents that are capable of specific hybridization with a nucleotide sequence of an RNA. Oligonucleotides are used for a variety of therapeutic and diagnostic purposes, such as treating diseases, regulating gene expression in experimental systems, assaying for RNA and for RNA products through the employment of antisense interactions with such RNA, diagnosing diseases, modulating the production of proteins, and cleaving RNA in site specific fashions. The compounds of the invention include novel heterocyclic bases, nucleosides, and nucleotides. When incorporated into oligonucleotides, the compounds of the invention can be useful for modulating the activity of RNA.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.